BIOA · BioAge Labs, Inc.
Market Cap
$436.02M
Shares
45.90M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$9M
FY2025
Net Income
-$80.61M
-13.4%
FY2025
Operating Margin
-1031.46%
FY2025
Diluted EPS
-$2.24
+66.2%
FY2025
Operating Cash Flow
-$81.63M
-58.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $10.36M | $9M | $0 | — | |
| $87.79M | $73.97M | $59.04M | $33.89M | |
| $28.84M | $27.81M | $19.16M | $14.51M | |
| $116.63M | $101.78M | $78.19M | $48.4M | |
| -$106.27M | -$92.78M | -$78.19M | -$48.4M | |
| — | -1031.46% | — | — | |
| $281K | $697K | $2.37M | $7.79M | |
| $11.81M | $12.18M | $7.09M | -$15.45M | |
| — | -$80.61M | -$71.11M | -$63.85M | |
| — | $0 | $0 | $0 | |
| -$94.46M | -$80.61M | -$71.11M | -$63.85M | |
| — | -896.11% | — | — | |
| -$95.15M | -$80.57M | -$71.03M | -$63.86M | |
| USD/shares | -$2.38 | -$2.24 | -$6.63 | -$38.17 |
| USD/shares | -$2.38 | -$2.24 | -$6.63 | -$38.17 |
| shares | — | 35.93M | 10.73M | 1.67M |
| shares | — | 35.93M | 10.73M | 1.67M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
11.84×
Peer median 1.89×
EV/EBIT
—
Peer median 18.36×
P/E (TTM)
—
Peer median 13.33×
Peer medians compare against the 47 similar-size Drug Manufacturers - Specialty & Generic companies (of 95 listed).
Valuation over time computed as of each quarter's filing date
Key facts
CIK
1709941
CUSIP
09077V100
13F (30d)
134 filings
131 filers
Visit website
Investor relations